Treatment of moderate to severe glabellar lines research hub

A phase III, multicentre, double-blind, randomised, placebo-controlled and open-label study to evaluate the efficacy and safety of a single dose of IPN10200 in the improvement of moderate to severe glabellar lines in adult participants, and to evaluate the long-term efficacy and safety of repeat doses of IPN10200 in the same indication.

This study is testing a new treatment, IPN10200, for moderate to severe frown lines between the eyebrows. We want to see if a single dose works well and is safe, and if repeat doses continue to work and remain safe over time.